Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets continue to trade weak
Fri, 1 Aug 11:30 am

After opening weak, the Indian stock markets have continued to trade below the dotted line during the morning trading session. Barring stocks from automobile and FMCG sectors all the other indices are trading in red. Maximum selling is witnessed in stocks from Capital goods and Oil and gas sector.

The BSE-Sensex is trading down 120 points. The NSE-Nifty is trading down 27 points. The BSE Mid Cap index is trading down 0.1% and the BSE Small Cap index is trading up 0.1%. The rupee is trading at 60.82 to the US dollar.

Most Software stocks are trading lower today. HCL Technologies and Tech Mahindra are leading the losers. India's fifth largest software firm Tech Mahindra, has announced results for 1QFY15. Consolidated revenues for the quarter grew by 1.25% QoQ to Rs 51.2 bn. In dollar terms, revenues were up 3.6 % QoQ and came in at US$ 855 m. While topline growth was decent, the company's operational performance was a little disappointing due to a huge increase in seasonal visa related costs. Operating margins declined by 3.1% QoQ and the operating profits fell by 13.4% QoQ. Net profits increased by 2.7% QoQ to Rs 6.3 bn. The growth was driven by a pickup in business momentum in the US as well as in enterprise services. Tech Mahindra is trading down 2.3% today.

Indian Pharma stocks are trading mixed with, Ranbaxy Ltd and Sun pharma being the leading losers, while Divis laboratories and Glenmark pharma are among the leading gainers in the pack. As per the financial daily, Cadila healthcare has received 483 from USFDA on one of its products manufactured at Moraiya facility in Gujarat. Reportedly, the company is in process of reviewing the documents of the product on which the 483 was issued. The company is assessing the filed ANDA before its approval and the observations are being responded accordingly. Further, it is also reported that there are no good manufacturing practices (GMP)-related issues and as such and no business impact. USFDA issues the 483s to the firm's management at the conclusion of an inspection when an investigator had observed conditions that in their judgment might constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts in the US. In approx a week's time Cadila is second company to receive 483 observations from USFDA. Few days back, even Ipca had received 483 letter from USFDA.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets continue to trade weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.